AIDS vaccine advisory committee
An ongoing Phase III study of Aventis-Pasteur's ALVAC vCP-1521 HIV vaccine with VaxGen's AIDSVAX will be discussed at FDA's Vaccines & Related Biologics Advisory Committee's Sept. 23 meeting. The meeting will be held at the Holiday Inn in Bethesda, Md. beginning at 9 a.m. The committee will be closed from 11 a.m. to 12:15 p.m. to discuss trade secret/confidential information [Editor's Note: To 1watch a webcast or order a video/DVD of this meeting, visit FDAAdvisoryCommittee.com.]...
You may also be interested in...
GSK achieved a first-in-class market oncology launch in 2020, but will have to increase that hit rate in order to fulfil its blockbuster ambitions.
The two companies can now market their HER-2 targeting antibody-drug conjugate in its second tumor type as they look to expand beyond breast cancer.
Coronavirus Notebook: EMA Data Hack Aimed At 'Undermining Trust' In Vaccines, Russia Plans EU Sputnik V Filing Next Month
France has reported on side-effect reports concerning the Pfizer/BioNTech vaccine, and the World Health Organization has warned that plans to provide global equitable access to coronavirus vaccines are at risk.